Article
Using high-throughput sequencing transcriptome data for INDEL detection: challenges for cancer drug discovery
Registro en:
WAJNBERG, Gabriel; PASSETTI, Fabio. Using high-throughput sequencing transcriptome data for INDEL detection: challenges for cancer drug discovery. Expert Opinion on Drug Discovery, v.11, n.3, p.257-268, 2016.
1746-0441
10.1517/17460441.2016.1143813
1746-045X
Autor
Wajnberg, Gabriel
Passetti, Fabio
Resumen
A cancer cell is a mosaic of genomic and epigenomic alterations. Distinct cancer molecular signatures can be observed depending on tumor type or patient genetic background. One type of genomic alteration is the insertion and/or deletion (INDEL) of nucleotides in the DNA sequence, which may vary in length, and may change the encoded protein or modify protein domains. INDELs are associated to a large number of diseases and their detection is done based on low-throughput techniques. However, high-throughput sequencing has also started to be used for detection of novel disease-causing INDELs. This search may identify novel drug targets. 2030-01-01